Successful Use of Eltrombopag in a Young Child With Chronic Immune Thrombocytopenia
Bernd Gruhn1, Achim Ehrnsperger2, Claudia Willy2
1Department of Pediatrics, Jena University Hospital, Jena, DEU.
Insights
Eltrombopag effectively managed chronic immune thrombocytopenia (ITP) in a young girl, maintaining stable platelet counts and reducing bleeding symptoms over years. This treatment offers a promising alternative to prolonged steroid or immunoglobulin therapies for pediatric ITP.
Area of Science:
- Pediatric Hematology
- Immunology
- Pharmacology
Background:
- Chronic immune thrombocytopenia (ITP) presents a significant challenge in pediatric care, often requiring long-term management.
- Current treatments for pediatric ITP, such as corticosteroids and intravenous immunoglobulins, can have substantial side effects and lead to frequent hospitalizations.
Observation:
- A retrospective case record of a young girl diagnosed with chronic ITP at 19 months old, treated with eltrombopag.
- The patient experienced a stable clinical response with reduced bleeding symptoms over several years.
- Platelet counts were effectively raised by eltrombopag, correlating with a decreased tendency for bleeding.
Findings:
- Eltrombopag demonstrated a stable and effective therapeutic response in a pediatric patient with chronic ITP.
- The treatment was well-tolerated, with no new safety concerns identified over more than 2.5 years of follow-up.
- Consistent dose adjustments were not necessary, indicating sustained efficacy.
Implications:
- Eltrombopag can be a beneficial treatment option for children with chronic ITP in routine clinical practice.
- Early intervention with thrombopoietin receptor agonists like eltrombopag may prevent frequent hospitalizations and reduce the need for prolonged corticosteroid or immunoglobulin therapies in children.
- This case supports the use of eltrombopag as a safe and effective long-term management strategy for pediatric chronic ITP.
Abstract:
The disease course in a young girl with chronic immune thrombocytopenia (ITP) at the initial age of 19 months, treated with eltrombopag, was evaluated retrospectively and is presented as a case record and discussed against the background of the available literature. A stable response and reduction in clinical symptoms, over several years and without frequent dose changes, was achieved. Bleeding symptoms were mild to moderate and occurred particularly frequently in combination with low platelet counts. Raising the platelet count, in turn, was accompanied by a decreased bleeding tendency. Eltrombopag was tolerated well. No new safety signals were observed during the treatment. Based on a follow-up of more than 2.5 years, our case confirms that a child with chronic ITP can benefit from treatment with eltrombopag in the regular care setting. We assume that early treatment with a thrombopoietin receptor agonist could save many children from repeated and lengthy hospitalizations with intravenous immunoglobulins and prolonged administration of corticosteroids.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption